Dietary supplementation with lactobacilli and bifidobacteria is well tolerated and not associated with adverse events during late pregnancy and early infancy

Journal of Nutrition

Volumn 140, Issue 3, 2010, Pages 483-488

  Allen, Stephen J ^a   Jordan, Susan ^b   Storey, Melanie ^a   Thornton, Catherine A ^a   Gravenor, Michael ^a   Garaiova, Iveta ^c   Plummer, Susan F ^c   Wang, Duolao ^d   Morgan, Gareth ^a  

^a SWANSEA UNIVERSITY   (United Kingdom)

^b SWANSEA UNIVERSITY   (United Kingdom)

^c Obsidian Research Limited   (United Kingdom)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CUL 08; CUL 20; CUL 34; CUL 61; PARACETAMOL; PLACEBO; PROBIOTIC AGENT; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; ATOPY; BIFIDOBACTERIUM; BIFIDOBACTERIUM ANIMALIS; BIFIDOBACTERIUM BIFIDUM; BRONCHIOLITIS; CHILD GROWTH; CLINICAL TRIAL; COLIC; COLONY FORMING UNIT; CONJUNCTIVITIS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG SCREENING; EAR DISEASE; ENDOCRINE DISEASE; FEEDING DISORDER; FEMALE; FOLLOW UP; GASTROENTERITIS; GASTROESOPHAGEAL REFLUX; HUMAN; IMPETIGO; INFANT; INFANT DISEASE; INFANT FEEDING; INFECTION; LACTOBACILLUS; LACTOBACILLUS PARACASEI; LACTOBACILLUS SALIVARIUS; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MATERNAL ATTITUDE; METABOLIC DISORDER; NEUROLOGIC DISEASE; NEVUS; NEWBORN JAUNDICE; NUTRITIONAL DISORDER; PARASITOSIS; PATIENT COMPLIANCE; PREGNANCY; PREGNANT WOMAN; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SYMPTOM; THRUSH; UPPER RESPIRATORY TRACT INFECTION; UROGENITAL TRACT DISEASE; VIRUS INFECTION;

ADULT; BIFIDOBACTERIUM; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERSENSITIVITY, IMMEDIATE; INFANT; INFANT, NEWBORN; LACTOBACILLUS; PREGNANCY; PREGNANCY TRIMESTER, THIRD; PROBIOTICS;

BACTERIA (MICROORGANISMS); BIFIDOBACTERIUM ANIMALIS SUBSP. LACTIS; BIFIDOBACTERIUM BIFIDUM; LACTOBACILLUS PARACASEI; LACTOBACILLUS SALIVARIUS;

EID: 77249103595     PISSN: 00223166     EISSN: 15416100     Source Type: Journal    
DOI: 10.3945/jn.109.117093     Document Type: Article

References (19)

1. FAO/WHO. Report on Joint FAO/WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria. 2001 [cited 2009 Oct 20]. Available from: ftp://ftp.fao.org/es/esn/food/probio-report-en. pdf.
2. FAO/WHO. Report of a Joint FAO/WHO Working Group on Drafting Guidelines for the Evaluation of Probiotics in Food. 2002 [cited 2009 Oct 20]. Available from: ftp://ftp.fao.org/es/esn/food/wgreport2.pdf.
3. Saavedra JM. Use of probiotics in pediatrics: rationale, mechanisms of action, and practical aspects. Nutr Clin Pract. 2007;22:351-65.
4. Wallace B. Clinical use of probiotics in the pediatric population. Nutr Clin Pract. 2009;24:50-9.
5. Boyle RJ, Robins-Browne RM, Tang ML. Probiotic use in clinical practice: what are the risks? Am J Clin Nutr. 2006;83:1256-64.
6. Snydman DR. The safety of probiotics. Clin Infect Dis. 2008;46: S104-11.
7. Besselink MGH, van Santvoort HC, Buskens E, Boermeester MA, van Goor H, Timmerman HM, Nieuwenhuijs VB, Bollen TL, van Ramshorst B, et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;371:651-9.
8. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use [cited 2009 Oct 20]. Available from: http://www.wctn.org.uk/downloads/EU- Directive/ Directive.pdf.
9. WHO. (2007). International statistical classification of diseases and related health problems. 10th revision. version for 2007 [cited 2009 Oct 20]. Available from: http://www.who.int/classifications/apps/icd/ icd10online/.
10. Dugoua JJ, Machado M, Zhu X, Chen X, Koren G, Einarson TR. Probiotic safety in pregnancy: a systematic review and meta-analysis of randomized controlled trials of Lactobacillus, Bifidobacterium, and Saccharomyces spp. J Obstet Gynaecol Can. 2009;31:542-52.
11. Collier R. Squabble over risks of probiotic infant formula. CMAJ. 2009;181:3-4.
12. Dekker JW, Wickens K, Black PN, Stanley TV, Mitchell EA, Fitzharris P, Tannock GW, Purdie G, Crane J. Safety aspects of probiotic bacterial strains Lactobacillus rhamnosus HN001 and Bifidobacterium animalis subsp. lactis HN019 in human infants aged 0-2 years. Int Dairy J. 2009;19:149-54.
13. Chouraqui JP, Grathwohl D, Labaune JM, Hascoet JM, de Montgolfier I, Leclaire M, Giarre M, Steenhout P. Assessment of the safety, tolerance, and protective effect against diarrhea of infant formulas containing mixtures of probiotics or probiotics and prebiotics in a randomized controlled trial. Am J Clin Nutr. 2008;87:1365-73.
14. Weizman Z, Alsheikh A. Safety and tolerance of a probiotic formula in early infancy comparing two probiotic agents: a pilot study. J Am Coll Nutr. 2006;25:415-9.
15. Puccio G, Cajozzo C, Meli F, Rochat F, Grathwohl D, Steenhout P. Clinical evaluation of a new starter formula for infants containing live Bifidobacterium longum BL999 and prebiotics. Nutrition. 2007;23:1-8.
16. Kukkonen K, Savilahti E, Haahtela T, Juntunen-Backman K, Korpela R, Poussa T, Tuure T, Kuitunen M. Long-term safety and impact on infection rates of postnatal probiotic and prebiotic (synbiotic) treatment: randomized, double-blind, placebo-controlled trial. Pediatrics. 2008;122:8-12.
17. Vlieger AM, Robroch A, van Buuren S, Kiers J, Rijkers G, Benninga MA, Te Biesebeke R. Tolerance and safety of Lactobacillus paracasei ssp. paracasei in combination with Bifidobacterium animalis ssp. lactis in a prebiotic-containing infant formula: a randomised controlled trial. Br J Nutr. 2009;102:869-75.
18. Gibson RA, Barclay D, Marshall H, Moulin J, Maire JC, Makrides M. Safety of supplementing infant formula with long-chain polyunsaturated fatty acids and Bifidobacterium lactis in term infants: a randomised controlled trial. Br J Nutr. 2009;101:1706-13.
19. Taylor AL, Dunstan JA, Prescott SL. Probiotic supplementation for the first 6 months of life fails to reduce the risk of atopic dermatitis and increases the risk of allergen sensitization in high-risk children: a randomized controlled trial. J Allergy Clin Immunol. 2007;119: 184-91.